Concord Biotech CFO Lalit Sethi announces early retirement

Concord Biotech Limited announced that Lalit Sethi, its chief financial officer and key managerial personnel, will retire early from his position due to personal reasons, effective close of business hours on January 5, 2026. The company informed both the National Stock Exchange of India Ltd. and BSE Limited on December 8, 2025, about this change, citing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sethi’s decision, communicated in a letter dated December 8, 2025, to Ankur Vaid, joint managing director & CEO, stems from personal priorities, including family commitments and health, as he approaches age 59. During his tenure, Sethi contributed to Concord's growth in operations, regulatory compliance, and IPO preparations, expressing confidence in the company's leadership.

He has committed to a seamless transition, including a complete handover of financial statements, compliance documentation, regulatory files, and investor relations materials. Concord Biotech has also announced the closure of its trading window for dealing in securities from Monday, December 8, 2025, for 48 hours.